ARLG
Antibacterial Resistance Leadership Group



Welcome!

January 2025, Q1 Newsletter

Thank you for supporting our mission to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Read more for important ARLG updates, including:

- Program highlights
- ARLG Spotlight: Deborah Collyar
- Events
- Study milestones
- New publications

News

ARLG Researchers Named in Clarivate's™ 2024 "Highly Cited Researchers" List

Clarivate

Clarivate's Highly Cited Researchers program identifies researchers who have significantly influenced their fields during the past year. Clarivate uses a meticulous process to identify individuals whose work has been most widely cited. Of the 6,886 Highly Cited Research awards issued in 2024, several ARLG members, including ARLG's Co-Principal Investigator Vance Fowler (Cross-Field), received recognition.

Other ARLG award recipients include Robert Bonomo (Immunology), Yohei Doi (Immunology, Pharmacology and Toxicology), Keith Kaye (Cross-Field), Barry Kreiswirth (Pharmacology and Toxicology), Amy Mathers (Cross-Field), Robin Patel (Cross-Field), David Paterson (Pharmacology and Toxicology), Ryan Shields (Cross-Field), David van Duin (Immunology), and more.

You can find the full list of ARLG award recipients on Clarivate™ with links to their profiles on Web of Science™. Congratulations, award recipients!

Congratulations Kerryl Greenwood-Quaintance!

Kerryl Greenwood-Quaintance, ARLG Laboratory Center Program Manager, successfully defended her doctoral thesis on December 13, 2024, earning a Doctor of Education in Leadership from Saint Mary's University of Minnesota. Well done, Kerryl!

Member Spotlight

Highlighting Deborah Collyar: ARLG Patient Advocate

Deborah Collyar
President, Patient Advocates In Research (PAIR) Network

Deborah Collyar, President of Patient Advocates In Research (PAIR Network), has served as a Patient Advocate in ARLG's INNOVATIONS Working Group since 2020, working on both the Quality of Life (QOL) and Desirability of

Outcome Ranking (DOOR) Task Forces. Deb is moving away from ARLG to focus on initiatives at the Institute at One Cancer Place and the Alliance for Rare Cancers.

Her work has helped the ARLG to broaden the scope of its trials beyond traditional approaches, to involve patient communities who may be at higher risk for infectious disease (ID) and antimicrobial resistance (AMR), and to incorporate a variety of patient perspectives in its research.

The ARLG is grateful for Deb's devotion and service to its INNOVATIONS Working Group. Dr. Vance Fowler, Dr. Sarah Doernberg, and Dr. Jessica Howard-Anderson have sent special notes to Deb expressing appreciation for her insights and contributions and wishing her all the best in her future endeavors.

Read More

Events

December 2024 Grand Rounds Now Available

If you missed the Grand Rounds on December 6, 2024, the ARLG Events page includes a link to the full video recording.

Check out *"The Pittsburgh Phage Program: A Four-Year Retrospective and Future Outlook"* presented by Ghady Haidar, MD, Associate Professor of Medicine, Division of Infectious Diseases, University of Pittsburgh.

Watch Now

8th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference

The 8th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference took place on January 15 – 17, 2025. Find out more information below including presentation titles by ARLG leadership and members such as Vance Fowler, David Roach, Natalie Mackow, Jessica Howard-Anderson, and Michael Woodworth.

Learn More

ESCMID Global 2025 Late-Breaking Abstract Submission

ESCMID Global

ESCMID Global 2025 takes place April 11-15, 2025 in Vienna, Austria. Late-breaking abstract submission will be open from February 3rd to February 14th, 2025.

Submit Now

Study Milestones

DOTS	**D**albavancin as an **O**ption for **T**reatment of **S**. aureus Bacteremia	Manuscript in Progress
PHAGE	Study of the Safety and Microbiological Activity of Bacterio**PHAGE**s in Persons with Cystic Fibrosis Colonized with *Pseudomonas aeruginosa*	Enrolling (80% enrolled)

Visit the ARLG Studies page below for more milestones and updates!

Learn More

New Publications

Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer A, Hujer K, van Duin D, Fowler Jr. V, Chambers HF, Kreiswirth BN, Bonomo RA for the Antibacterial Resistance Leadership Group. A Molecular Analysis of Meropenem-Vaborbactam Non-Susceptible KPC-Producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0020824. doi: 10.1128/aac.00208-24.

Hareza DA, Cosgrove SE, Bonomo RA, Dzintars K, Karaba SM, Hayes AM, Tekle T, Simner PJ, Tamma PD. Clinical Outcomes and Emergence of Resistance of *Pseudomonas aeruginosa* Infections Treated with Ceftolozane-tazobactam versus Ceftazidime-avibactam. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0090724. doi: 10.1128/aac.00907-24.

Jacobs MR, Good CE, Abdelhamed AM, Mack AR, Bethel CR, Marshall S, Patel R, van Duin D, Fowler Jr. VG, Rhoads DD, Hujer AM, Hujer KM, Six DA, Moeck G, Papp-Wallace KM, Bonomo RA. Argonaut-IV: Susceptibility of Carbapenemase-Producing Klebsiella pneumoniae to the Oral Bicyclic Boronate B-Lactamase Inhibitor Ledaborbactam Combined With Ceftibuten. Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0112724. doi: 10.1128/aac.01127-24.

Jiang J, Komarow L, Hill C, Boutzoukas AE, Hanson B, Arias CA, Bonomo RA, Evans S, Doi Y, Satlin MJ, Chambers HF, Fowler Jr. VG, van Duin D, Kreiswirth BN, Chen L. for the Antibacterial Resistance Leadership Group. Molecular Epidemiology and Clinical Characterization of Carbapenemase-producing Enterobacter species from an International Cohort. J Infect Dis. 2024 Dec 12:jiae616. doi: 10.1093/infdis/jiae616. Epub ahead of print.

Banerjee R, Giri A, Komarow L, Souli M, Doernberg SB, Patel R. for the Antibacterial Resistance Leadership Group. Impact of Rapid Antibiotic Susceptibility Testing for Gram-negative Bacteremia Varies by Pathogen Type and Resistance: A Secondary Analysis of the RAPIDS GN Trial. Microbiol Spectr. 2024 Dec 16:e0178924. doi: 10.1128/spectrum.01789-24.

Visit the ARLG Publications page below for a full list of published work!

View More